Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Zealand Pharma - Execution framework for share buy-back program
Company announcement No. 15 / 2026 Zealand Pharma - Execution framework for share buy-back program Copenhagen, Denmark, May 7, 2026 – Zealand Pharma A/S ('the Company' or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a…
Zealand Pharma Announces Financial Results for the First Three Months of 2026
Company announcement – No. 14 / 2026 Zealand Pharma Announces Financial Results for the First Three Months of 2026 A defining start to 2026, marked by pivotal progress for leading obesity assets, petrelintide and survodutide, and strong…
Angelini Pharma to Buy Catalyst in Deal Worth $4.1 Billion
Italian drugmaker Angelini Pharma SpA agreed to buy Catalyst Pharmaceuticals Inc. for $4.1 billion as it looks to grow in the US and build a footprint in rare diseases. Angelini Pharma will pay $31.50 per share in cash for Catalyst, a 21% premium…
BridgeBio Pharma: Q1 Earnings Snapshot
PALO ALTO, Calif. (AP) — PALO ALTO, Calif. (AP) — BridgeBio Pharma Inc. (BBIO) on Thursday reported a loss of $164 million in its first quarter. The Palo Alto, California-based company said it had a loss of 84 cents per share. The…
Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program
Company announcement No. 13 / 2026 Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program Robust cash position of USD 2.3 billion (DKK 14.5 billion) as of March 31, 2026 Financial strength to be further enhanced by…
Indian companies pledge to invest record $20.5 billion in US; pharma in focus
Indian companies have pledged to invest a record $20.5 billion in the United States, which includes $19.1 billion in pharmaceuticals, the US embassy said on Wednesday. The commitments were made during an investment summit in Maryland, US. According…
Big Pharma Runs Its Checkout Counter Through GoodRx
Pharma Direct, the unit that connects pharmaceutical manufacturers directly to consumers through point-of-sale pricing programs, grew 82% year over year in Q1. The platform now runs more than 125 self-pay programs. GoodRx handled approximately one…
Health deserts, hospital windfalls, and a phalanx of pharma lobbyists: Inside the most controversial healthcare program you never heard of
Keith Harvey is CEO of Cook Area Health Services, better known as Scenic Rivers Health, a group of nonprofit medical and dental clinics in the northeast Minnesota hinterlands. Scenic Rivers Health struggles to make the most of a mysterious federal…
Citigroup Raises Royalty Pharma (NASDAQ:RPRX) Price Target to $66.00
Royalty Pharma (NASDAQ:RPRX - Get Free Report) had its target price boosted by analysts at Citigroup from $50.00 to $66.00 in a report issued on Thursday, Benzinga reports. The firm currently has a 'buy' rating on the biopharmaceutical company's…
Ascendis Pharma A/S Q1 Earnings Call Highlights
Can BioMarin Stock Live Up to Wall Street's High Expectations? Ascendis Pharma A/S NASDAQ: ASND reported first-quarter 2026 results highlighted by the U.S. FDA approval of its third TransCon product, YUVIWEL, and continued growth across its rare…
Vanguard Group Inc. Cuts Stake in Royalty Pharma PLC $RPRX
Vanguard Group Inc. reduced its position in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 9.2% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 9,934,612 shares of the biopharmaceutical company's…
JPMorgan Chase & Co. Issues Positive Forecast for Royalty Pharma (NASDAQ:RPRX) Stock Price
Royalty Pharma (NASDAQ:RPRX - Get Free Report) had its price objective increased by equities researchers at JPMorgan Chase & Co. from $50.00 to $58.00 in a report released on Thursday, Benzinga reports. The firm currently has an 'overweight' rating…
Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up After Strong Earnings
Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) gapped up before the market opened on Thursday after the company announced better than expected quarterly earnings. The stock had previously closed at $45.30, but opened at $55.36. Zealand Pharma…
Inside the fast-tracked FDA
This is a preview of the May 1 edition of Access Health— Tap here to get this newsletter delivered straight to your inbox on Thursday mornings. Good morning. This week, I attended the launch event for the West Health Accelerator at the…
Tracking Tweedy Browne Portfolio - Q1 2026 Update (NYSEARCA:COPY)
Tweedy Browne's Q1 2026 13F portfolio rose to ~$1.26B with 93 holdings, led by CNH Industrial (17.61%). Significant portfolio concentration: top five positions (CNH, Ionis Pharma, Berkshire Hathaway, Coca-Cola FEMSA, and Alphabet) comprise ~57%.
Receive a Daily briefing on Pharma Industry News
Get Started